Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Immunic, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JULY 9, 2026 /PRNEWSWIRE/ -- IMMUNIC , INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES IN JULY: JULY 14-15: LEERINK PARTNERS THERAPEUTICS FORUM.ERIK LUNDGREN, CHIEF EXECUTIVE OFFICER, JASON TARDIO, PRESIDENT AND CHIEF OPERATING OFFICER, MICHAEL A.

IMMUNIC TO PARTICIPATE IN INVESTOR CONFERENCES IN JULY

NEW YORK, JUNE 10, 2026 /PRNEWSWIRE/ -- IMMUNIC , INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INVESTOR, INDUSTRY AND SCIENTIFIC CONFERENCES IN JUNE: JUNE 15-16: H.C. WAINWRIGHT 7TH ANNUAL NEURO PERSPECTIVES EXPERT SUMMIT.

IMMUNIC TO PARTICIPATE IN INVESTOR, INDUSTRY AND SCIENTIFIC CONFERENCES IN JUNE

 LATE-BREAKING POSTER INTRODUCES NEW UNIFIED STATISTICAL ANALYSES FOR ASSESSING CONFIRMED DISABILITY CHANGES FOR TRIALS IN PROGRESSIVE MULTIPLE SCLEROSIS   ADDITIONAL CALLIPER DATA FURTHER HIGHLIGHT VIDOFLUDIMUS CALCIUM'S FAVORABLE SAFETY AND TOLERABILITY PROFILE; PATIENT-REPORTED OUTCOMES ASSESSMENTS SHOW NO NEGATIVE IMPACT ON MOOD  NEW YORK, MAY 28, 2026 /PRNEWSWIRE/ -- IMMUNIC , INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC DISEASES, TODAY ANNOUNCED THE PRESENTATION OF ONE LATE-BREAKING AND TWO ADDITIONAL POSTERS HIGHLIGHTING ADDITIONAL DATA FROM ITS PHASE 2 CALLIPER TRIAL EVALUATING LEAD ASSET, NUCLEAR RECEPTOR-RELATED 1 (NURR1) ACTIVATOR, VIDOFLUDIMUS CALCIUM (IMU-838) IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS (PMS) AT THE 2026 CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS (CMSC) ANNUAL MEETING, TAKING PLACE MAY 27-29, 2026 IN CHARLOTTE, NC. ALL POSTER PRESENTATIONS WILL BE ACCESSIBLE ON THE "EVENTS AND PRESENTATIONS" SECTION OF IMMUNIC'S WEBSITE AT: HTTPS://IR.IMUX.COM/EVENTS-AND-PRESENTATIONS.

IMMUNIC TO PRESENT ADDITIONAL PHASE 2 CALLIPER TRIAL DATA FOR VIDOFLUDIMUS CALCIUM AT THE CMSC ANNUAL MEETING 2026, REINFORCING ITS POTENTIAL IN PROGRESSIVE MULTIPLE SCLEROSIS

 PROVEN LEADER WITH DEEP MULTIPLE SCLEROSIS EXPERTISE; PLAYED KEY ROLE IN THE LAUNCH OF OCREVUS   WILL LEVERAGE SENIOR GLOBAL EXECUTIVE AND COMMERCIAL EXPERIENCE TO SUPPORT IMMUNIC'S TRANSITION TOWARD A COMMERCIAL-STAGE MULTIPLE SCLEROSIS COMPANY  NEW YORK, MAY 27, 2026 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF DISTINGUISHED BIOPHARMACEUTICAL EXECUTIVE ERIK LUNDGREN AS CHIEF EXECUTIVE OFFICER, EFFECTIVE MAY 22, 2026, WITH EMPLOYMENT BEGINNING ON JUNE 1, 2026. MR. LUNDGREN SUCCEEDS DANIEL VITT, PH.D.

IMMUNIC APPOINTS DISTINGUISHED BIOPHARMACEUTICAL EXECUTIVE ERIK LUNDGREN AS CHIEF EXECUTIVE OFFICER

 MORE THAN 30 YEARS OF LEADERSHIP EXPERIENCE ACROSS BIOPHARMACEUTICAL COMMERCIALIZATION   PLAYED KEY ROLE IN THE LAUNCH AND COMMERCIAL SUCCESS OF AVONEX FOR MULTIPLE SCLEROSIS  NEW YORK, MAY 19, 2026 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF MICHAEL "MIKE" W. BONNEY, A HIGHLY EXPERIENCED BIOPHARMACEUTICAL EXECUTIVE AND BOARD LEADER, AS CHAIR OF ITS BOARD OF DIRECTORS, EFFECTIVE MAY 16, 2026.

IMMUNIC APPOINTS SEASONED BIOPHARMACEUTICAL EXECUTIVE MICHAEL W. BONNEY AS CHAIR OF THE BOARD OF DIRECTORS

 APPOINTED GLOBALLY RENOWNED BIOPHARMACEUTICAL EXECUTIVE AND NEUROLOGY DRUG DEVELOPER, MICHAEL A. PANZARA, M.D.

IMMUNIC, INC. REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEW YORK, APRIL 30, 2026 /PRNEWSWIRE/ -- IMMUNIC , INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INVESTOR AND MEDICAL CONFERENCES IN MAY: MAY 4-6 AND 12-13: 26TH BIOQUITY EUROPE. DANIEL VITT, PH.D.

IMMUNIC TO PARTICIPATE IN INVESTOR AND MEDICAL CONFERENCES IN MAY

 PROVEN LEADER IN NEUROLOGY DRUG DEVELOPMENT, INCLUDING FOR SEVERAL APPROVED MULTIPLESCLEROSIS THERAPIES   STRONG EXPERIENCE IN ADVANCING LATE-STAGE CLINICAL PROGRAMS AND OBTAINING GLOBAL REGULATORY APPROVALS, KEY TO SUPPORTING VIDOFLUDIMUS CALCIUM THROUGH PIVOTAL DEVELOPMENT  NEW YORK, APRIL 28, 2026 /PRNEWSWIRE/ -- IMMUNIC, INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF MICHAEL A. PANZARA, M.D.

IMMUNIC APPOINTS ACCOMPLISHED BIOPHARMACEUTICAL EXECUTIVE MICHAEL A. PANZARA, M.D.

NEW YORK, APRIL 23, 2026 /PRNEWSWIRE/ -- IMMUNIC , INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC DISEASES (THE "COMPANY" OR "IMMUNIC"), TODAY ANNOUNCED THAT IT WILL EFFECT A REVERSE STOCK SPLIT OF ITS OUTSTANDING SHARES OF COMMON STOCK, EFFECTIVE AS OF 12:01 A.M. EASTERN TIME ON APRIL 27, 2026.

IMMUNIC, INC. ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT

NEW YORK, APRIL 9, 2026 /PRNEWSWIRE/ -- IMMUNIC , INC. (NASDAQ: IMUX),A LATE-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL ORAL THERAPIES FOR NEUROLOGIC DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING SCIENTIFIC AND MEDICAL CONFERENCES IN APRIL: APRIL 14-16: 8TH ANNUAL NEUROIMMUNOLOGY DRUG DEVELOPMENT SUMMIT. HELLA KOHLHOF, PH.D.

Immunic, Inc.

IMUX

Price

Financial Reports

No items found.

Press Releases

Immunic, Inc.

IMUX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMUX